OR WAIT null SECS
Takeda’s TAKHZYRO prefilled syringe is now available for patients with hereditary angioedema aged 12 years and older in the United States.
Takeda announced on April 18, 2022 that its treatment TAKHZYRO (lanadelumab-flyo) injection single-dose prefilled syringe is now available in the United States to prevent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.
HAE is a rare genetic disease that causes recurrent attacks of swelling in various parts of the body, which can be burdensome, debilitating, and potentially life-threatening. The treatment is ready-to-use and is easier to administer as it requires fewer preparation steps than a single-dose vial. FDA approved the treatment on Feb. 8, 2022.
“HAE attacks are unpredictable, debilitating, and in some cases life-threatening, adding uncertainty and complexity to the daily lives of those living with this disease and their families,” said Dr. William Lumry, allergy immunology specialist, clinical professor of internal medicine, University of Texas Southwestern Medical School, in a press release. “After many years in practice witnessing the ups and downs of this disease, I welcome any opportunity to simplify the process of administering an effective prevention therapy for people living with HAE."
“By introducing TAKHZYRO prefilled syringe to the HAE community, our aim is to continue to enhance the patient experience. With this advancement, those taking TAKHZYRO can now live their life with a ready-to-use option that requires fewer steps and less waste than when using the single-dose vial to receive their injection,” said Cheryl Schwartz, senior vice president, Rare Disease Business Unit at Takeda Pharmaceutical Company Limited, in the release. “Over the coming months, we will be working with patients and their specialty pharmacies as they are ready to make the transition.”